ILC 2019: First-in-class entry inhibitor bulevirtide (Myrcludex B) effective and well tolerated in combination with PEG-IFN-a in Phase 2b study involving individuals with chronic hepatitis B/D virus coinfection, producing high rates of viral suppression both on and off treatment with…
ILC 2019: Randomized controlled study reports favourable virological outcomes with simplified monitoring of glecaprevir/pibrentasvir treatment in chronic hepatitis C infection 13 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER) A randomized controlled study (SMART-C) designed…
ILC 2019: Latest study suggests that integration of hepatitis B virus (HBV) DNA into the human genome is not restricted to the early phases of chronic HBV infection but also frequently occurs in individuals with hepatitis B e antigen (HBeAg)-negative…
ILC 2019: ‘Real-world’ studies confirm the effectiveness of elbasvir/grazoprevir in people with hepatitis C (HCV) genotype 1 infection who inject and/or abuse drugs or who receive opioid substitution therapy 13 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY…
ILC 2019: Interim data from two Phase 2a studies of ABI-H0731 suggest good tolerability and enhanced antiviral efficacy in combination with standard-of-care in chronic hepatitis B infection 13 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE…
ILC 2019: German and US studies confirm the efficacy and safety of G/P in a broad range of individuals with HCV infection and other comorbidities, showing improvements in mental and physical well-being 12 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION…
ILC 2019: Orally-administered small molecule, ccc_R08, eliminates covalently closed circular DNA (cccDNA) in the liver of an HBV cccDNA mouse model: a step towards a sterilizing cure? 12 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE…
ILC 2019: ‘Treatment as Prevention’ programme for hepatitis C in Iceland reports high levels of cure, but homelessness is found to be a barrier to success 11 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER)…
ILC 2019: ‘Real-world’ studies in Germany and the USA confirm high rates of sustained virological response with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in individuals with chronic HCV infection failing DAAs 10 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY OF THE…